Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
| Wednesday, June 10th | 1pm ET / 10am PT | Presented by: Rho
Interest in using electronic patient reported outcomes (ePRO) on smart devices is on the rise. In this webinar, Emily Cantrell and Becky Baggett will share lessons learned working on a large phase 3 pain study that utilizes ePRO on tablet devices. Register Now!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!